LONDON, March 25, 2014 /PRNewswire/ --
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quest Diagnostics Inc. (NYSE: DGX), Organovo Holdings Inc. (NYSE MKT: ONVO), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Free technical research on DGX, ONVO, A, and TMO can be downloaded upon signing up at:
http://www.investor-edge.com/447-register
On Monday, shares in Quest Diagnostics Inc. finished the session 0.45% lower at $55.52. The stock recorded trading volume of 1.90 million shares as compared to a three months average volume of 2.38 million shares. The stock fluctuated between $55.22 and $55.90 during the session. Shares of the company traded at a PE ratio of 14.82. Quest Diagnostics Inc's stock has fallen by 0.52% in the previous three trading sessions, while the same has gained 3.18% in the last one month and 3.70% on YTD basis. The stock is trading above its 50-day moving average. Quest Diagnostics Inc's 200-day moving average of $58.03 is trading above the 50-day moving average of $53.26. Moreover, the stock is trading at a Relative Strength Index (RSI) of 68.88. Sign up today to read free research on DGX at:
http://www.investor-edge.com/447-DGX-24Mar2014.pdf
Shares in Organovo Holdings Inc. reported a trading volume of 1.84 million shares, as compared with a three months average volume of 3.32 million shares. The stock ended the day at $8.38, down 0.83% and at an intraday range of $8.01 and $8.38. Organovo Holdings Inc's shares have declined 6.58% in the previous three trading sessions, 18.80% in the last month, and 24.30% on YTD basis. The stock is trading above its 200-day moving average. Organovo Holdings Inc's 50-day moving average of $9.79 is trading above the 200-day moving average of $7.48. Furthermore, the stock is trading at an RSI of 35.28. Sign up today to read free research on ONVO at:
http://www.investor-edge.com/447-ONVO-24Mar2014.pdf
On Monday, shares in Agilent Technologies Inc. fell 1.48% to close at $55.26. A total of 1.99 million shares were traded, which is below the three months average volume of 2.75 million. The stock oscillated between $54.66 and $56.23 during the trading session. Shares of the company traded at a PE ratio of 21.92. Agilent Technologies Inc's shares have fallen by 2.42% in the previous three trading sessions, 2.63% in the last one month, and 3.37% on YTD basis. The stock is trading above its 200-day moving average. Agilent Technologies Inc's 50-day moving average of $57.90 is trading above the 200-day moving average of $51.70. Furthermore, the stock is trading at an RSI of 44.21. Sign up today to read free research on A at:
http://www.investor-edge.com/447-A-24Mar2014.pdf
Shares in Thermo Fisher Scientific Inc. recorded a trading volume of 2.76 million shares, as compared with a three months average volume of 2.51 million shares. The stock ended the day at $120.65, down 1.83% after vacillating between $119.35 and $123.56. Shares of the company traded at a PE ratio of 34.50. Thermo Fisher Scientific Inc's shares have fallen by 1.69% in the previous three trading sessions and 2.20% in the last one month, and have gained 8.35% on YTD basis. Further, the company's stock is trading above its 50-day and 200-day moving averages. Thermo Fisher Scientific Inc's 50-day moving average of $119.64 is trading above the 200-day moving average of $100.64. Additionally, shares of the company are trading at an RSI of 50.95. Sign up today to read free research on TMO at:
http://www.investor-edge.com/447-TMO-24Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://Investor-Edge.com
SOURCE Investor-Edge
